Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 265-280 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Stem cell source

  • Alvaro Urbano-Ispizua, MD, PhD (Consultant in Hematology)

      Affiliations

    • Corresponding Author InformationTel.: +34 93 454 9543; Fax: +34 93 453 1263.

References 

  1. Gratwohl A, Baldomero H, Passweg J, et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplantation. 2002;30:813–831
  2. Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoetic stem cell transplantation in Europe. Blood. 2002;100:2374–2386
  3. Gratwohl A, Passweg J, Baldomero H, et al. Economics, health care systems and utilisation of haematopoietic stem cell transplants in Europe. British Journal of Haematology. 2002;117:451–468
  4. Gratwohl A, Baldomero H, Passweg J, et al. Hematopoetic stem cell transplantation for hematological malignancies in Europe. Leukemia. 2003;17:941–959
  5. Gratwohl A, Baldomero H, Demirer T, et al. Hematopoetic stem cell transplantation for solid tumours in Europe. Annals of Oncology. 2004;15:653–660
  6. Gratwohl A, Baldomero H, Schmid O, et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplantation. 2005;36:575–590
  7. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood. 1993;81:2031–2035
  8. Sheridan WP, Begely CG, Juttner CA, et al. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640–644
  9. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony-stimulating factor. Blood. 1993;81:1883–1888
  10. Switzer GE, Goycoolea JM, Dew MA, et al. Donating stimulated peripheral blood stem cells versus bone marrow: do donors experience the procedures differently?. Bone Marrow Transplantation. 2001;27:917–923
  11. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia. 2005;19:822–828
  12. Pulsipher MA, Nagler A, Iannone R, et al. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatric Blood & Cancer. 2006;46:422–433
  13. Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood. 1984;64:630–634
  14. Stroncek DF, Holland PV, Bartch G, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993;81:1940–1946
  15. Confer DL. Hematopoietic cell donors. In:  Blume KG,  Forman SJ,  Appelbaum F editor. Thomas' Hematopoietic Cell Transplantation. vol. 1:Malden, Massachusetts: Blackwell Publishing; 2004;p. 538–549
  16. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996–2003. Bone Marrow Transplantation. 2005;35:361–367
  17. Grupp SA, Frangoul H, Wall D, et al. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatric Blood & Cancer. 2006;46:414–421
  18. Martínez C, Urbano-Ispizua A, Marín P, et al. Efficacy and toxicity of high dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplantation. 1999;24:1273–1278
  19. Martínez C, Urbano-Ispizua A, Mazzara R, et al. Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects. Blood. 1996;87:4916–4917
  20. Anderlini P, Donato M, Lauppe J, et al. Allogeneic blood stem cell collection: 4-year results of the MD Anderson protocol in normal donors. Blood. 1998;92(supplement 1):120a;[Abstract 485]
  21. Majolino I, Cavallaro AM, Bacigalupo A, et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). Haematologica. 1997;82:47–52
  22. Tabilio A, Falzetti F, Giannoni C, et al. Stem cell mobilization in normal donors. Journal of Hematotherapy. 1997;6:227–234
  23. de la Rubia J, Martinez C, Solano C, et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplantation. 1999;24:723–728
  24. Hernandez JM, Castilla C, Gutierrez NC, et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia. 2005;19:1088–1091
  25. Nagler A, Korenstein-Ilan A, Amiel A, et al. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Experimental Hematology. 2004;32:122–130
  26. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology. 2002;3:687–694
  27. Papayannopoulou T, Priestley GV, Bonig H, et al. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. Blood. 2003;101:4739–4747
  28. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848
  29. Kollet O, Petit I, Kahn J, et al. Human CD34(+) CXCR4(−) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood. 2002;100:2778–2786
  30. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. The Journal of Experimental Medicine. 1997;185:111–120
  31. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. The Journal of Clinical Investigation. 2003;111:187–196
  32. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 2001;97:3354–3360
  33. Burroughs L, Mielcarek M, Little MT, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood. 2005;106:4002–4008
  34. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Experimental Hematology. 2002;30:973–981
  35. Larochelle A, Krouse A, Metzger M, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood. 2006;107:3772–3778
  36. Gerlach LO, Skerlj RT, Bridger GJ, et al. Molecular interactions of cyclam and bicyclam nonpeptide antagonists with the CXCR4 chemokine receptor. The Journal of Biological Chemistry. 2001;276:14153–14160
  37. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Letters. 2002;527:255–262
  38. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–833
  39. Deichmann M, Kronenwett R, Haas R. Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood. 1997;89:3522–3528
  40. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728–2730
  41. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45:295–300
  42. Spencer A, Jackson J, Baulch-Brown C. Enumeration of bone marrow ‘homing’ haemopoietic stem cells from G-CSF-mobilised normal donors and influence on engraftment following allogeneic transplantation. Bone Marrow Transplantation. 2001;28:1019–1022
  43. Podesta M. Transplantation hematopoiesis. Current Opinion in Hematology. 2001 Nov;8(6):331–336
  44. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. The New England Journal of Medicine. 1989;21:1174–1178
  45. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. The New England Journal of Medicine. 1996;335:157–166
  46. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88:795–802
  47. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood. 2003;102:4290–4297
  48. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–1618
  49. Rocha V, Wagner JE, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. The New England Journal of Medicine. 2000;342:1846–1854
  50. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. The New England Journal of Medicine. 1997;337:373–381
  51. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–2971
  52. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood. 2001;97:2957–2961
  53. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood. 1999;93:3662–3671
  54. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. The New England Journal of Medicine. 1998;339:1565–1577
  55. Brunstein CG, Wagner JE. Umbilical cord blood transplantation and banking. Annual Review of Medicine. 2006;57:403–417
  56. de Lima M, Shpall E. Strategies for widening the use of cord blood in hematopoietic stem cell transplantation. Haematologica. 2006;91:584–587
  57. Barker JN, Weisdorf D, Wagner J. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. The New England Journal of Medicine. 2001;344:1871
  58. Barker JN, Weisdorf D, Defor T, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1347
  59. Fernandez MN, Regidor C, Cabrera R, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive cotransplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Experimental Hematology. 2003;102:1915–1919
  60. Magro E, Regido C, Cabrera R, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica. 2006;91:640–648
  61. Shpall E, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biology of Blood and Marrow Transplantation. 2002;8:376
  62. McNiece I, Kubegov D, Kerzic P, et al. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Experimental Hematology. 2000;28:1181–1186
  63. Noort WA, Kruisselbrink AB, Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Experimental Hematology. 2002;30:870–878
  64. Niederwieser D, Gentilini C, Hegenbart U, et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors?. Bone Marrow Transplantation. 2004;34:657–665
  65. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. Journal of Clinical Oncology. 2000;18:1360–1377
  66. Dercksen MW, Rodenhuis S, Dirkson MKA, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral blood stem cell transplantation. Journal of Clinical Oncology. 1995;13:1922–1932
  67. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97:383–387
  68. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allo-transplantation: does the source of hematopoietic stem cells matter?. Blood. 2001;98:2900–2908
  69. Talarn C, Urbano-Ispizua A, Martino R, et al. G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplantation. 2006;37:873–879
  70. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. The New England Journal of Medicine. 2001;344:1815–1822
  71. Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–3934
  72. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226–4235
  73. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726–2733
  74. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–767
  75. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470
  76. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–3227
  77. Urbano-Ispizua A, Rozman C, Pimentel P, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood. 2001;100:724–727
  78. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia. 2003;17:869–875
  79. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102:1108–1113
  80. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  81. Weiden PL, Sullivan KM, Flournoy NF, et al. Antileukemic effect of chronic graft-versus-host disease. The New England Journal of Medicine. 1981;304:1529–1533
  82. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1728
  83. Urbano-Ispizua A, Carreras E, Marín P, et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings: detrimental effect of a high number of donor CD34+ cells?. Blood. 2001;98:2352–2357
  84. Pan L, Delmonte J, Jalonen C, et al. Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes T-lymphocytes towards type-2 cytokine production and reduced severity of experimental graft-versus-host-disease. Blood. 1995;86:4422–4429
  85. Zaucha JM, Gooley T, Heimfeld S, et al. The ratio of CD3:CD14 cells and the number of CD34 cells in G-CSF mobilized peripheral blood mononuclear cell (G-PBMC) products are significantly associated with clinical outcome in HLA-identical sibling transplantation. Blood. 2000;96(supplement 1):205a
  86. Waller EK, Rosenthal H, Jones TW, et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood. 2001;97:2948–2956
  87. Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. British Journal of Haematology. 2005;128:659–667
  88. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England Journal of Medicine. 2001;344:175–181
  89. Couban S, Simpson D, Barnett M, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Canadian Bone Marrow Transplant Group. Blood. 2002;100:1525–1531
  90. Blaise D, Kuentz M, Fortainier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Francaise de Greffe de Moelle. Journal of Clinical Oncology. 2000;18:537–546
  91. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone marrow stem-cell transplantation in haematological malignant diseases. a randomised trial. Lancet. 2000;355:1231–1237
  92. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Blood. 2002;100:3128–3134
  93. Heldal D, Brinch L, Tjonnfjord G, et al. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. Bone Marrow Transplantation. 2003;32:257–264
  94. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation. Journal of Clinical Oncology. 2001;19:3685–3691
  95. Flowers M, Parker P, Johnston L, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100:415–419
  96. Elmaagacli AH, Beelen DW, Opalka B, et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood. 1999;94:384–389
  97. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705–4709
  98. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. The New England Journal of Medicine. 1999;341:14–21
  99. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–3709
  100. Elfenbein G, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Experimental Hematology. 2004;32:327–339
  101. Isola LM, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplantation. 1997;20:1033–1037
  102. Couban S, Messner HA, Andreou P, et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: A study of 29 patients. Biology of Blood and Marrow Transplantation. 2000;6:422–427
  103. Serody S, Sparks SD, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biology of Blood and Marrow Transplantation. 2000;6:434–440
  104. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF) primed allogeneic bone marrow: significantly less graft-vs-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood. 2001;98:3186–3191
  105. Ji Q, Chen HR, Wang X, et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation. 2002;8:261–267
  106. Elfenbein GJ, Sackstein R, Oblon DJ. Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No!. Blood Cells Molecules & Diseases. 2004;32:106–111

PII: S1521-6926(06)00066-1

doi: 10.1016/j.beha.2006.09.006

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 265-280 , June 2007

Article Tools

* Image Usage & Resolution